WO2008020306A3 - Isoindole derivatives - Google Patents

Isoindole derivatives Download PDF

Info

Publication number
WO2008020306A3
WO2008020306A3 PCT/IB2007/002469 IB2007002469W WO2008020306A3 WO 2008020306 A3 WO2008020306 A3 WO 2008020306A3 IB 2007002469 W IB2007002469 W IB 2007002469W WO 2008020306 A3 WO2008020306 A3 WO 2008020306A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
isoindole derivatives
salts
schizophrenia
formula
Prior art date
Application number
PCT/IB2007/002469
Other languages
French (fr)
Other versions
WO2008020306A2 (en
Inventor
David Alan Favor
James Jeffrey Powers
Joseph Thomas Repine
Andrew David White
Original Assignee
Pfizer Prod Inc
David Alan Favor
James Jeffrey Powers
Joseph Thomas Repine
Andrew David White
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, David Alan Favor, James Jeffrey Powers, Joseph Thomas Repine, Andrew David White filed Critical Pfizer Prod Inc
Publication of WO2008020306A2 publication Critical patent/WO2008020306A2/en
Publication of WO2008020306A3 publication Critical patent/WO2008020306A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

This invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, a process of making these compounds, pharmaceutical compositions containing one or more of these compounds or their salts, and their use for the treatment of schizophrenia, bipolar disorder, or other central nervous system disorders.
PCT/IB2007/002469 2006-08-18 2007-08-15 Isoindole derivatives WO2008020306A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82276706P 2006-08-18 2006-08-18
US60/822,767 2006-08-18

Publications (2)

Publication Number Publication Date
WO2008020306A2 WO2008020306A2 (en) 2008-02-21
WO2008020306A3 true WO2008020306A3 (en) 2008-11-06

Family

ID=38740296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002469 WO2008020306A2 (en) 2006-08-18 2007-08-15 Isoindole derivatives

Country Status (2)

Country Link
AR (1) AR062405A1 (en)
WO (1) WO2008020306A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589764A (en) * 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
JP5656364B2 (en) * 2009-04-20 2015-01-21 株式会社トクヤマ Method for producing naphthopyran derivatives
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
GB201101959D0 (en) 2011-02-04 2011-03-23 Univ Nottingham Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease
EP2816037A3 (en) 2011-05-24 2015-04-01 Università degli Studi di Bari "Aldo Moro" New 1-arylpiperazinic ligands of 5-HT7 receptor and use thereof
CN104981472A (en) * 2012-11-08 2015-10-14 辉瑞大药厂 Heteroaromatic compounds and their use as dopamine d1 ligands
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
MA41169A (en) * 2014-12-17 2017-10-24 Acraf WIDE-SPECTRUM ANTIBACTERIAL COMPOUNDS
CN105153013B (en) * 2015-09-16 2017-12-29 苏州昊帆生物科技有限公司 The synthetic method of the ketone of 6 bromine isoindoline 1
CN106749219A (en) 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 A kind of lactam derivative and its application
CN105859732B (en) * 2016-04-11 2018-04-06 浙江海正药业股份有限公司 The technique for preparing AD 35

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066165A1 (en) * 2003-12-31 2005-07-21 Warner-Lambert Company Llc N-substituted piperidine and piperazine derivatives
WO2007026959A2 (en) * 2005-08-31 2007-03-08 Otsuka Pharmaceutical Co., Ltd. Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066165A1 (en) * 2003-12-31 2005-07-21 Warner-Lambert Company Llc N-substituted piperidine and piperazine derivatives
WO2007026959A2 (en) * 2005-08-31 2007-03-08 Otsuka Pharmaceutical Co., Ltd. Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders

Also Published As

Publication number Publication date
WO2008020306A2 (en) 2008-02-21
AR062405A1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
WO2008020306A3 (en) Isoindole derivatives
WO2009016410A3 (en) Chemical compounds 831
UA102517C2 (en) Substituted morpholine and thiomorpholine derivatives, pharmaceutical composition based thereon and use thereof for the preparation of medicament for the treatment of a disorder or disease of the central nervous system
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
TW200612892A (en) Novel compounds
MX2010008469A (en) Pyrazolopyrimidines, a process for their preparation and their use as medicine.
JO2686B1 (en) compounds
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
MX2011012122A (en) Thiophene derivatives.
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
MX346186B (en) Protein kinase inhibitors.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
GEP20135806B (en) Lactams as beta secretase inhibitors
TW200716204A (en) Pharmaceutical composition
TW200626158A (en) Naphthaline derivatives
MX2007010400A (en) Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MY144132A (en) Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isoproproxypyridin)yl]-4-penten-2-amine
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MX2007006387A (en) 3-substituted pyridine derivatives as h3 antagonists.
MX2009006010A (en) Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases.
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2006077024A3 (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789674

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789674

Country of ref document: EP

Kind code of ref document: A2